Table 3

Conditional logistic regression model of cardiovascular events, stratified by subgroup

Subgroup	n	A1C (%)	Odds ratio (95% CI)^*	P
LDL <100, no other CV drug^†	20,871	≤6	1.39 (1.15–1.67)	0.0006
LDL <100, no other CV drug^†		>8	1.20 (1.03–1.40)	0.02
LDL >100, no other CV drug^†	13,983	≤6	1.05 (0.79–1.39)	0.74
LDL >100, no other CV drug^†		>8	1.41 (1.18–1.69)	0.0002
On other cardiovascular drug, LDL <100^†	9,555	≤6	1.10 (0.85–1.43)	0.45
On other cardiovascular drug, LDL <100^†		>8	1.25 (0.95–1.63)	0.11
On other cardiovascular drug, LDL >100^†	4,038	≤6	0.89 (0.39–2.01)	0.78
On other cardiovascular drug, LDL >100^†		>8	1.32 (0.70–2.49)	0.39
Patients using antipsychotics^‡	2,539	≤6	1.05 (0.53–2.07)	0.90
Patients using antipsychotics^‡		>8	3.15 (1.18- 8.44)	0.02
Patients not using antipsychotics^†	53,246	≤6	1.26 (1.15–1.38)	<0.0001
Patients not using antipsychotics^†		>8	1.17 (1.09–1.26)	<0.0001

LDL units are in mg/dl. Other cardiovascular drugs include antiplatelets and antihypertensives other than ACE inhibitors and ARBs.
↵*Odds ratio for A1C category compared with A1C 6–8% (reference).
↵†Not on antipsychotics. Model controlled for number of A1C tests in the 3-year index period, A1C range, diabetes medications, proportion of days covered of diabetes medications, use of statins, ACE inhibitors, ARBs, antiarrhythmics, tricyclic antidepressants, ESAs, β-agonists, diagnosis of hypertension, heart failure or peripheral vascular disease, retinopathy, nephropathy, neuropathy, prior cardiovascular events in 3-year preindex period, and severe hypoglycemia.
↵‡Model controlled for prior cardiovascular events, HDL level, use of β-agonists, and ESAs.